Back to today’s briefing

Story perspectives

Solid Biosciences Aims to Transform Rare Disease Treatments

1/14/2025

47 6

Summary

Story summary

Bo Cumbo, CEO of Solid Biosciences, is on a mission to revolutionize treatments for Friedreich’s ataxia and Duchenne muscular dystrophy. Following a merger with AavantiBio, Solid has made strides with SGT-212, which targets both brain and heart. With FDA approval for direct delivery, human trials are set to begin in late 2025, as competitors like Voyager Therapeutics also push forward.

1 of 1

Story summary

Bo Cumbo, CEO of Solid Biosciences, is on a mission to revolutionize treatments for Friedreich’s ataxia and Duchenne muscular dystrophy. Following a merger with AavantiBio, Solid has made strides with SGT-212, which targets both brain and heart. With FDA approval for direct delivery, human trials are set to begin in late 2025, as competitors like Voyager Therapeutics also push forward.